Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Abstract

Among patients receiving recommended therapy for heart failure, those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group, regardless of the presence or absence of diabetes. (Funded by Boehringer Ingelheim and Eli Lilly; EMPEROR-Reduced ClinicalTrials.gov number, NCT03057977.).

Keywords

Affiliated Institutions

• Kyushu University JP
• St. Michael's Hospital CA
• Boehringer Ingelheim (Taiwan) TW
• Harvard University US
• London School of Hygiene & Tropical Medicine GB
• Seoul National University KR
• Ospedale Papa Giovanni XXIII IT
• Universitätsklinikum Würzburg DE
• Washington DC VA Medical Center US
• Saarland University DE
• Monash University AU
• National Institute for Health Research GB
• Imperial Valley College US
• University of Toronto CA
• McGill University Health Centre CA
• Wroclaw Medical University PL
• Universidade de São Paulo BR
• Maastricht University Medical Centre NL
• University of London GB
• NIHR Biomedical Research Centre at The Royal Marsden and the ICR
• Glenfield Hospital GB
• Instituto Nacional de Cardiología MX
• Cedars-Sinai Medical Center US
• Hospital El Cruce AR
• Max Super Speciality Hospital IN
• Massachusetts General Hospital US
• University of Glasgow GB
• Baylor University Medical Center US
• University of Leicester GB
• Université de Lorraine FR
• Centre Hospitalier Universitaire de Besançon FR
• University of Mannheim DE
• Berlin Institute of Health at Charité - Universitätsmedizin Berlin DE
• Universidade de Santiago de Compostela ES
• Boehringer Ingelheim (Germany) DE
• French Clinical Research Infrastructure Network FR
• University of Pisa IT
• Boehringer Ingelheim (United States) US
• Semmelweis University HU
• University of Mississippi US
• University Hospital Brno CZ
• National and Kapodistrian University of Athens GR
• Heidelberg University DE
• Chinese Academy of Medical Sciences & Peking Union Medical College CN
• Boehringer Ingelheim (Canada) CA

Related Publications